Last reviewed 2026-05-13 · How we verify

Rimegepant 75mg Orally Disintegrating Tablets (ODT) (rimegepant-75mg-orally-disintegrating-tablets-odt)

Rimegepant 75mg Orally Disintegrating Tablets (ODT) (generic name: rimegepant-75mg-orally-disintegrating-tablets-odt) is a calcitonin gene-related peptide receptor antagonist Small molecule drug developed by Pfizer. It is currently FDA-approved for Acute treatment of migraine attacks with or without aura in adults.

Rimegepant is a calcitonin gene-related peptide receptor antagonist.

Rimegepant 75mg Orally Disintegrating Tablets (ODT), developed by Pfizer, holds a niche position in the migraine treatment market, competing against established brands like Sumatriptan, Nurtec ODT, Imitrex, and Rizatriptan. Its competitive advantage lies in its unique mechanism as a calcitonin gene-related peptide receptor antagonist, offering an alternative to traditional triptans. A key risk is the lack of ongoing clinical trials, which may limit future expansion and innovation. The pipeline outlook remains uncertain due to the absence of new clinical trials and the requirement for a PD-L1 companion diagnostic for several potential indications.

At a glance

Mechanism of action

Rimegepant works by blocking the action of calcitonin gene-related peptide (CGRP), a molecule involved in the transmission of pain signals in the brain. This mechanism of action is unique compared to other migraine treatments, which often target other pathways. By blocking CGRP, rimegepant reduces the frequency and severity of migraine attacks.

Approved indications

• Acute treatment of migraine attacks with or without aura in adults

Common side effects

• COVID-19
• Upper respiratory tract infection
• Hyperuricaemia
• Nasopharyngitis
• Hyperlipidaemia
• Pyrexia
• Weight increased
• Oropharyngeal pain
• Hepatic function abnormal
• Weight decreased
• Cough
• Sinus arrhythmia

Drug interactions

• Warfarin
• P-glycoprotein inhibitors (e.g., cyclosporine, ketoconazole)
• P-glycoprotein inducers (e.g., rifampin, St. John's Wort)
• CYP3A4 inhibitors (e.g., ketoconazole, itraconazole)
• CYP3A4 inducers (e.g., rifampin, St. John's Wort)
• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole)
• Strong CYP3A4 inducers (e.g., rifampin, St. John's Wort)

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Rimegepant 75mg Orally Disintegrating Tablets (ODT) CI brief — competitive landscape report
• Rimegepant 75mg Orally Disintegrating Tablets (ODT) updates RSS · CI watch RSS
• Pfizer portfolio CI

Frequently asked questions about Rimegepant 75mg Orally Disintegrating Tablets (ODT)

Related

• Drug class: All calcitonin gene-related peptide receptor antagonist drugs
• Target: All drugs targeting calcitonin gene-related peptide receptor
• Manufacturer: Pfizer — full pipeline
• Therapeutic area: All drugs in Neuroscience
• Indication: Drugs for Acute treatment of migraine attacks with or without aura in adults
• Compare: Rimegepant 75mg Orally Disintegrating Tablets (ODT) vs similar drugs
• Pricing: Rimegepant 75mg Orally Disintegrating Tablets (ODT) cost, discount & access